Compare AI & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | ARDX |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2020 | 2014 |
| Metric | AI | ARDX |
|---|---|---|
| Price | $9.26 | $6.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $14.00 | ★ $15.14 |
| AVG Volume (30 Days) | ★ 4.5M | 3.1M |
| Earning Date | 05-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $389,056,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.27 | N/A |
| 52 Week Low | $7.68 | $3.50 |
| 52 Week High | $30.24 | $8.40 |
| Indicator | AI | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 62.31 |
| Support Level | $7.70 | $5.49 |
| Resistance Level | $9.58 | $6.70 |
| Average True Range (ATR) | 0.51 | 0.23 |
| MACD | 0.18 | 0.09 |
| Stochastic Oscillator | 69.32 | 94.96 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.